Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Abstract: We provide an alkylation process, comprising: separating and recycling a hydrogen gas and a hydrogen chloride from an offgas of a hydrogenation reactor; wherein the hydrogen gas is recycled to the hydrogenation reactor; and wherein the hydrogen chloride is recycled to an alkylation reactor. We also provide an alkylation process unit for performing this process.

Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.

Abstract: Processes for eliminating oxygenates and water from a light hydrocarbon processing system, wherein oxygenates are removed from a light hydrocarbon stream by adsorption of the oxygenates on an oxygenate adsorption unit to provide a deoxygenated hydrocarbon stream, the oxygenate adsorption unit is regenerated via a regenerant stream to provide an oxygenated regenerant stream comprising the oxygenates, and the oxygenated regenerant stream is subjected to hydro-deoxygenation to convert the oxygenates into paraffins and water, wherein the water may also be permanently removed from the system.

Abstract: Processes for eliminating water and oxygenates from a light hydrocarbon processing system, wherein oxygenates are removed from a light hydrocarbon stream by adsorption of the oxygenates on a primary oxygenate adsorption unit to provide a deoxygenated hydrocarbon stream, the primary oxygenate adsorption unit is regenerated via a first regenerant stream to provide an oxygenated first regenerant stream, the oxygenated first regenerant stream is deoxygenated via a secondary oxygenate adsorption unit, and the secondary oxygenate adsorption unit is regenerated via a second regenerant stream to provide an oxygenated second regenerant stream for permanent removal from the system.

Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Abstract: Methods for converting an H2SO4 alkylation unit to an ionic liquid alkylation system configured for performing ionic liquid catalyzed alkylation processes may comprise connecting at least one component configured for ionic liquid catalyzed alkylation to at least one component of the H2SO4 alkylation unit, wherein the at least one component of the H2SO4 alkylation unit is retained, modified or adapted for use in the ionic liquid alkylation system. Ionic liquid catalyzed alkylation systems derived from existing conventional alkylation units, and ionic liquid catalyzed alkylation processes are also disclosed.

Abstract: Methods for converting an HF alkylation unit to an ionic liquid alkylation system configured for performing ionic liquid catalyzed alkylation processes may comprise connecting at least one component configured for ionic liquid catalyzed alkylation to at least one component of the HF alkylation unit, wherein the at least one component of the HF alkylation unit is retained, modified or adapted for use in the ionic liquid alkylation system. An ionic liquid alkylation system derived from an existing or prior HF alkylation unit is also disclosed.

Abstract: An anhydrous antiperspirant composition comprising a dehydrated alum salt, a water soluble calcium salt, and a liquid carrier material comprising 50% or more by weight of hydrophobic oils.

Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.

Abstract: A system and method directed at a consumer interaction system and program that provides an option to participate in said program, and provides incentives for participating in certain defined behavior, such as dimming the screen of or rendering silent a phone during the showing of a movie in a movie theater, participating in an activity in a particular geographic area, or making purchases.

Abstract: A method for reducing perspiration comprising the application to the surface of the human body of an alum salt and calcium chloride and compositions suitable for use in said method, in particular anhydrous compositions comprising both an alum salt and calcium chloride.

Abstract: We provide an alkylation process, comprising: separating and recycling a hydrogen gas and a hydrogen chloride from an offgas of a hydrogenation reactor; wherein the hydrogen gas is recycled to the hydrogenation reactor; and wherein the hydrogen chloride is recycled to an alkylation reactor. We also provide an alkylation process unit for performing this process.

Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

Abstract: We provide an alkylation process, comprising: separating and recycling a hydrogen gas and a hydrogen chloride from an offgas of a hydrogenation reactor; wherein the hydrogen gas is recycled to the hydrogenation reactor; and wherein the hydrogen chloride is recycled to an alkylation reactor. We also provide an alkylation process unit for performing this process.

Abstract: Spray compositions and particularly anhydrous aerosol compositions containing particulate antiperspirant actives exhibit a tendency for nozzle blockage, impeding discharge of the contents when a polyol humectant, such as glycerol, is blended into its base composition. The problem is overcome or at least ameliorated by preparation of a base composition, suitable for employment in conjunction with a propellant, that contains a low molecular weight (liquid) polyethylene glycol (PEG) as humectant, and particularly a PEG of molecular weight 150 to 500.

Abstract: Methods for converting an HF alkylation unit to an ionic liquid alkylation system configured for performing ionic liquid catalyzed alkylation processes may comprise connecting at least one component configured for ionic liquid catalyzed alkylation to at least one component of the HF alkylation unit, wherein the at least one component of the HF alkylation unit is retained, modified or adapted for use in the ionic liquid alkylation system. An ionic liquid alkylation system derived from an existing or prior HF alkylation unit is also disclosed.

Abstract: Methods for converting an H2SO4 alkylation unit to an ionic liquid alkylation system configured for performing ionic liquid catalyzed alkylation processes may comprise connecting at least one component configured for ionic liquid catalyzed alkylation to at least one component of the H2SO4 alkylation unit, wherein the at least one component of the H2SO4 alkylation unit is retained, modified or adapted for use in the ionic liquid alkylation system. Ionic liquid catalyzed alkylation systems derived from existing conventional alkylation units, and ionic liquid catalyzed alkylation processes are also disclosed.

Abstract: Tetrahydroindole derivatives of formula (I): are disclosed. These compounds modulate the activity of gamma-secretase and hence find use in treatment or prevention of Alzheimer's disease.

Abstract: [1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.